Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 48.8% in December

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 32,200 shares, a decrease of 48.8% from the December 15th total of 62,900 shares. Based on an average trading volume of 209,700 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.6% of the shares of the company are short sold.

Alzamend Neuro Trading Up 1.8 %

Shares of ALZN stock opened at $1.15 on Tuesday. The stock has a fifty day simple moving average of $1.27 and a two-hundred day simple moving average of $2.12. Alzamend Neuro has a 52-week low of $1.06 and a 52-week high of $15.06.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets dropped their price target on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Monday, December 16th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.